Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday

Vistagen Therapeutics (NASDAQ:VTGN) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Vistagen Therapeutics to post earnings of ($0.40) per share for the quarter.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative return on equity of 35.12%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the prior year, the firm earned ($0.94) EPS. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Price Performance

Shares of VTGN stock opened at $3.11 on Friday. The firm has a 50-day moving average of $3.13 and a 200-day moving average of $3.62. The company has a market cap of $84.16 million, a P/E ratio of -2.10 and a beta of 0.78. Vistagen Therapeutics has a one year low of $2.45 and a one year high of $5.86.

Analyst Upgrades and Downgrades

Separately, William Blair upgraded shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.